FB Chart FB data by YCharts

Facebook ( FB)

Facebook operates as a social networking company. I've been bearish on Facebook since before the IPO. I haven't found a reasonable edge investors can achieve from buying this one.

Sure, Facebook may increase in price; after all, I predict the odds, not the future. Subsequently, after factoring in downside risk I can't suggest buying shares. I'm not implying the Web site isn't great or it's not the best in class from a user point of view. I simply mean we can find lower-hanging fruit that offers a better opportunity.

52-Week Range: $17.55 to $45

Price To Book: 5.3

Expect the upcoming first-quarter earnings report after the market closes on Wednesday. The analysts' consensus earnings assessment is 13 cents a share. Analysts are estimating as low as 10 cents per share, up to the most optimistic estimate of 16 cents per share.

Unlike my pessimistic view, over half of the analysts covering Facebook rate it as a buy or strong buy, 21 of the 37 analysts covering the company give a buy recommendation, 14 analysts rate it a hold and two recommend selling.

Additionally, Facebook now has nine analysts rating the company as a strong buy, up from eight a month ago. However, the number of analysts rating Facebook a strong buy during the last three months has shifted higher and lower. Overall, if you own Facebook, you may not have my bullish opinion, but at least the major analysts are in favor of the investment idea.

Earnings have been a mixed bag for the stock in the short time since its IPO. Expect a lot of volatility. If you're an investor who wants to sleep at night, look to sell call options before the earnings release as a means to hedge your position. It's also an ideal time to gain the outsized premium. FB Revenue Quarterly Chart FB Revenue Quarterly data by YCharts

If you liked this article you might like

Apple Watch Issues Pull Nasdaq to Session Lows, Dow and S&P 500 in Flux

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux

The 6 Medications Being Used to Tackle the Opioid Epidemic

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Friday Selloff May Be On Its Way; Tenet Gears Up for Sale -- ICYMI